Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240027 | 0.81 | ALDH1A1 (0.51) | NPSR1KDM4EPKMRCE1ALDH1A1 | |
| SCHEMBL29679379 | 0.81 | ALDH1A1 (0.51) | NPSR1KDM4EPKMRCE1ALDH1A1 | |
| SCHEMBL14966295 | 0.81 | ALDH1A1 (0.50) | NPSR1KDM4EALDH1A1L3MBTL1MAPT | |
| SCHEMBL24344299 | 0.80 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL610102 | 0.80 | S1PR4 (0.56) | NPSR1KDM4EPKMRCE1ALDH1A1 | |
| SCHEMBL29625298 | 0.80 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL21332494 | 0.80 | NPSR1 (0.48) | NPSR1KDM4EPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL23530046 | 0.79 | NPSR1 (0.47) | NPSR1KDM4EPKMALDH1A1L3MBTL1 | |
| SCHEMBL2349201 | 0.79 | NPSR1 (0.47) | NPSR1KDM4EPKMRCE1ALDH1A1 | |
| SCHEMBL15390591 | 0.79 | KDM4E (0.50) | NPSR1KDM4EPKMRCE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934518-B1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2934518-B1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2020-02-19 | — | — | EP | disclosed |
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
| EP-2934518-A1 | SPIROCYCLIC CETP INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014099836-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014099836-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | NPSR1 327/4885KDM4E 2809/4885PKM 3602/4885 |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | CETP, MTTP, LCAT | NPSR1 3225/4885KDM4E 4131/4885PKM 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.